Welcome to our dedicated page for Churchill Capital XI SEC filings (Ticker: CCXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.Churchill Capital Corp XI director Paul Lapping filed an initial Form 3, which records his status as a director and establishes his baseline beneficial ownership reporting position. The filing shows no reported transactions or derivative positions and serves as a compliance disclosure for his new insider role.
Churchill Capital Corp XI director Stephen Anthony Murphy filed an initial ownership report on Form 3. The data provided shows no reported transactions or holdings, with buy, sell, acquire, and dispose share counts all at zero and net activity neutral.
Churchill Capital Corp XI reported governance changes, appointing Paul Lapping and Stephen Murphy to its board of directors, effective immediately. Both will join the compensation and audit committees, with Lapping becoming chair of the audit committee, replacing William Sherman, who remains a committee member.
The company entered into director agreements with Sherman, Lapping and Murphy providing cash compensation of $75,000 per year starting April 1, 2026. Lapping and Murphy also signed the existing sponsor letter agreement, waiving certain redemption rights and agreeing to vote their shares in favor of an initial business combination, and each entered into a standard director indemnification agreement.
Empyrean Capital Partners, LP and Amos Meron report beneficial ownership of 3,500,000 Class A ordinary shares of Churchill Capital Corp XI, representing 8.35% of this share class. The percentage is based on 41,900,000 Class A ordinary shares outstanding as of December 18, 2025.
The shares are directly held by Empyrean Capital Overseas Master Fund, Ltd., for which Empyrean acts as investment manager and Meron is an indirect control person through the general partner. They state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Fort Baker Capital Management LP and related parties reported a 5.4% beneficial stake in Churchill Capital Corp XI’s units. They collectively hold 2,252,979 units, each unit consisting of one Class A ordinary share and one-tenth of one redeemable warrant.
The percentage is based on 41,900,000 units outstanding as of December 18, 2025, as disclosed by the issuer. The reporting persons state the holdings are in the ordinary course of business, are not for changing or influencing control, and that they are filing jointly but each disclaims membership in a group and beneficial ownership beyond their pecuniary interest.
Magnetar-affiliated investment entities have disclosed a significant passive stake in Churchill Capital Corp XI. As of December 31, 2025, Magnetar Financial LLC, Magnetar Capital Partners LP, Supernova Management LLC and David J. Snyderman collectively reported beneficial ownership of 2,700,000 Class A ordinary shares, equal to approximately 6.44% of the outstanding shares.
The stake is held across several Magnetar funds, and all voting and investment power over these shares is exercised on their behalf. The ownership percentage is based on 41,900,000 Class A shares outstanding, as reported by the company. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Churchill Capital Corp XI.
MMCAP International Inc. SPC and Asset Management Inc. have amended their ownership report on Churchill Capital Corp XI, disclosing beneficial ownership of 2,700,000 Class A Ordinary Shares, representing 5.8% of the class as of 12/31/2025.
The shares are held with shared voting and dispositive power and no sole voting or dispositive power. The reporting persons certify the holdings were not acquired to change or influence control of Churchill Capital Corp XI, consistent with a passive Schedule 13G filing.
Adage Capital Management and affiliates have filed a Schedule 13G reporting a significant ownership stake in Churchill Capital Corp XI. Through Adage Capital Partners, they report beneficial ownership of 2,700,000 Class A ordinary shares, representing 6.44% of the outstanding Class A shares.
The 6.44% figure is based on 41,900,000 Class A ordinary shares outstanding after the company’s offering, private placement, and full exercise of the underwriters’ over-allotment option. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Churchill Capital Corp XI.
Churchill Capital Corp XI filed an 8-K to announce that its units will begin separate trading into common shares and warrants. Starting February 9, 2026, each unit, which currently trades under the symbol CCXIU, can be split into one Class A ordinary share and one-tenth of one redeemable warrant.
The Class A ordinary shares will trade on the Nasdaq Global Market under the symbol CCXI, and the whole warrants will trade under CCXIW. No fractional warrants will be issued, and any units that are not separated will continue to trade as units under the CCXIU symbol. Holders must work through their brokers and the transfer agent to complete the separation.